Thomas Büttner

ORCID: 0000-0003-0316-9621
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Acute Ischemic Stroke Management
  • Cerebrovascular and Carotid Artery Diseases
  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Monoclonal and Polyclonal Antibodies Research
  • Systemic Lupus Erythematosus Research
  • Urinary and Genital Oncology Studies
  • Neurological disorders and treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Prostate Cancer Treatment and Research
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Peptidase Inhibition and Analysis
  • Social and Demographic Issues in Germany
  • Genetic Neurodegenerative Diseases
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Advanced MRI Techniques and Applications
  • Photoacoustic and Ultrasonic Imaging
  • Esophageal Cancer Research and Treatment
  • Peripheral Neuropathies and Disorders
  • Cancer Genomics and Diagnostics
  • PI3K/AKT/mTOR signaling in cancer
  • Social Policy and Reform Studies
  • Labor market dynamics and wage inequality
  • Advanced Causal Inference Techniques

University Hospital Bonn
2022-2025

University of Bonn
2024

Integrated Oncology (United States)
2024

University Medical Centre Mannheim
2024

Heidelberg University
2024

University Hospital Heidelberg
2024

Klinikum Vest
2023

University of Zurich
2023

Bielefeld University
2023

Laboratory Krone
2023

PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit only achieved in a small, yet uncharacterized patient subset. NECTIN4 located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) cancer. Here, we aimed to evaluate amplifications as genomic biomarker predict EV response mUC. MATERIALS AND METHODS We established NECTIN4-specific fluorescence...

10.1200/jco.23.01983 article EN cc-by Journal of Clinical Oncology 2024-04-24

Abstract Seventy‐seven families with autosomal dominant cerebellar ataxia were analyzed for the CAG repeat expansions causing spinocerebellar (SCA) types 1, 2, 3, and 6. The SCA1 mutation accounted 9%, SCA2 10%, SCA3 42%, SCA6 22% of German families. Seven 27 patients had no family history ataxia. Age at onset correlated inversely length in all subtypes. Yet average effect one unit on age was different each SCA subtype. We compared clinical, electrophysiological, magnetic resonance imaging...

10.1002/ana.410420615 article EN Annals of Neurology 1997-12-01

Background and Purpose Elevations of protein S-100 (S-100) in cerebrospinal fluid serum have been reported after cerebral infarctions. The aim our study was to evaluate the time course concentrations territorial middle artery (MCA) infarctions correlation with clinical data prognosis. Methods levels were serially determined 26 patients an acute infarction territory MCA at day 0 (within 12 hours onset symptoms), 1 (24 stroke onset), days 2, 3, 4, 5, 7 or 8, 10 age- sex-matched control...

10.1161/01.str.28.10.1961 article EN Stroke 1997-10-01

People with brain injuries involving the amygdala are often poor at recognizing facial expressions of fear, but extent to which this impairment compromises other signals emotion fear has not been clearly established. We investigated N.M., a person bilateral damage and left thalamic lesion, who was impaired from expressions. N.M. showed an equivalent deficit affecting recognition body postures emotional sounds. His linked evidence any problem in anger (a common feature reports), for his...

10.1098/rspb.1999.0945 article EN Proceedings of the Royal Society B Biological Sciences 1999-12-22

<h3>Backround and aims:</h3> The aetiopathogenesis of Crohn’s disease, an inflammatory bowel disease (IBD), is not yet fully understood. Autoimmune mechanisms are thought to play a role in the development but target antigens underlying pathways have been sufficiently identified. <h3>Methods:</h3> Based on data from immunoblotting matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrometry, major antigenic pancreatic autoantibodies (PABs), which specific for was...

10.1136/gut.2008.162495 article EN Gut 2009-06-22

Significantly elevated plasma levels of homocysteine, but not cysteine and cysteinylglycine, were found in treated parkinsonian patients compared to controls. Elevated homocysteine may be either caused by an unknown endogenous metabolic disturbance or antiparkinsonian treatment, because no association severity duration disease was found. Based on the results this study one speculate that independent risk factor for vascular Parkinson's disease.

10.1159/000007984 article EN European Neurology 1998-01-01

Everywhere the advent of industrial society and correspondingly high incomes has been accompanied by a fall in births. If one could only explain unambiguously policy measures to counter it be readily devised. Unfortunately there are many explanations, from each follows different prescription. If income derived women's work offices industry become so that they cannot afford time have children, then payments State cover what lose through child raising will offset that. obstacle is cost...

10.2307/1972835 article EN Population and Development Review 1990-09-01

Abstract Introduction Analysis of autoantibodies (AAB) by indirect immunofluorescence (IIF) is a basic tool for the serological diagnosis systemic rheumatic disorders. Automation autoantibody IIF reading including pattern recognition may improve intra- and inter-laboratory variability meet demand cost-effective assessment large numbers samples. Comparing automated visual interpretation, usefulness routine laboratory diagnostics was investigated. Methods Autoantibody detection on human...

10.1186/ar2949 article EN cc-by Arthritis Research & Therapy 2010-03-09
Ondřej Fiala Sebastiano Buti Hideki Takeshita Y. Okada Francesco Massari and 87 more Geòrgia Anguera Michele Dionese Sarah Scagliarini Thomas Büttner Giuseppe Fornarini Zin Myint Luca Galli Vinícius Carrera Souza Renate Pichler Ugo De Giorgi María Natalia Gandur Quiroga Danielle Gilbert Lazar Popović Enrique Grande Giulia Mammone Rossana Berardi Simon J. Crabb Javier Molina‐Cerrillo Marcelo Freitas Murilo Luz Roberto Iacovelli Fabio Calabrò Deniz Tural Francesco Atzori Zsófia Kürönya Rita Chiari Saul Campos‐Gómez Orazio Caffo André P. Fay Jakub Kucharz Paolo Andrea Zucali José Augusto Rinck Annalisa Zeppellini Diogo Assed Bastos Gaetano Aurilio Augusto Mota Karine Martins da Trindade Cinzia Ortega Juan Pablo Sade Mimma Rizzo Nuno Vau Patrizia Giannatempo Allan Barillas Fernando Sabino Marques Monteiro Breno Dauster Carlo Cattrini Lucas Nogueira Roni de Carvalho Fernandes Emmanuel Seront Luis García Aceituno Francesco Grillone Hernan Javier Cutuli Mauricio Fernández Maria Bassanelli Giandomenico Roviello Halima Abahssain Giuseppe Procopio Michèle Milella Jindřich Kopecký Angelo Martignetti Carlo Messina Manuel Caitano Eva Inman Ravindran Kanesvaran Daniel Herchenhorn Daniele Santini Ray Manneh Kopp Renato Bisonni Roubini Zakopoulou Alessandra Mosca Francesco Morelli Fernando Cotait Maluf Andrey Soares Fernando Furlan Nunes Álvaro Pinto Anca Zgură Lorena Incorvaia Jawaher Ansari Ignacio Ortego Zabalza Johannes Landmesser Alessandro Rizzo Veronica Mollica Giulia Sorgentoni Nicola Battelli Camillo Porta Joaquim Bellmunt Matteo Santoni

10.1007/s00262-023-03518-z article EN Cancer Immunology Immunotherapy 2023-09-07
Francesco Massari Matteo Santoni Hideki Takeshita Y. Okada José Carlos Tapia and 92 more Umberto Basso Marco Maruzzo Sarah Scagliarini Thomas Büttner Giuseppe Fornarini Zin Myint Luca Galli Vinícius Carrera Souza Renate Pichler Ugo De Giorgi Nathalia Gandur Elaine T. Lam Danielle Gilbert Lazar Popović Enrique Grande Giulia Mammone Rossana Berardi Simon J. Crabb ROBERT COLEMAN KEMP Javier Molina‐Cerrillo Marcelo Freitas Murilo Luz Roberto Iacovelli Fabio Calabrò Deniz Tural Francesco Atzori Zsófia Kürönya Rita Chiari Saul Campos‐Gómez Orazio Caffo André P. Fay Jakub Kucharz Paolo Andrea Zucali José Augusto Rinck Annalisa Zeppellini Diogo Assed Bastos Gaetano Aurilio Augusto Mota Karine Martins da Trindade Cinzia Ortega Juan Pablo Sade Mimma Rizzo Ondřej Fiala Nuno Vau Patrizia Giannatempo Allan Barillas Fernando Sabino Marques Monteiro Breno Dauster Alessia Mennitto Lucas Nogueira Roni de Carvalho Fernandes Emmanuel Seront Luis García Aceituno Francesco Grillone Hernan Javier Cutuli Mauricio Fernández Maria Bassanelli Ray Manneh Kopp Giandomenico Roviello Halima Abahssain Giuseppe Procopio Michèle Milella Jindřich Kopecký Angelo Martignetti Carlo Messina Manuel Caitano Eva Inman Ravindran Kanesvaran Daniel Herchhorn Daniele Santini Aristotelis Bamias Renato Bisonni Alessandra Mosca Francesco Morelli Fernando Cotait Maluf Andrey Soares Fernando Furlan Nunes Álvaro Pinto Anca Zgură Lorena Incorvaia Jawaher Ansari Ignacio Ortego Zabalza Johannes Landmesser Alessandro Rizzo Veronica Mollica Andrea Marchetti Matteo Rosellini Giulia Sorgentoni Nicola Battelli Sebastiano Buti Camillo Porta Joaquim Bellmunt

Abstract Background Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods Medical records with documented metastatic UC treated by as second-line therapy were retrospectively collected from 88 institutions 23 countries. assessed for overall survival (OS),...

10.1007/s00262-024-03682-w article EN cc-by Cancer Immunology Immunotherapy 2024-04-18

Robust biomarkers to predict response immune checkpoint blockade (ICB) in metastatic urothelial carcinoma (mUC) are still demand. Recently, early C-reactive protein (CRP) kinetics and especially the novel CRP flare-response phenomenon has been associated with immunotherapy response.We conducted a multicentre observational study comprising 154 patients mUC treated ICB evaluate predictive value of previously described on-treatment kinetics: flare responders (at least doubling baseline within...

10.1016/j.ejca.2022.02.022 article EN cc-by European Journal of Cancer 2022-03-30

About 20% of patients with renal cell carcinoma present non-clear histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role cytoreductive nephrectomy (CN) in metastatic nccRCC is contentious. Limited data exist on CN under current standard care. This retrospective study focused impact upfront outcomes first-line immune checkpoint inhibitor (IO) combinations or tyrosine kinase (TKI) monotherapy. The included 221 and...

10.1007/s11523-024-01065-w article EN cc-by-nc Targeted Oncology 2024-05-05

715 Background: The prospective phase 3 study EV-302 demonstrated superiority regarding efficacy of Enfortumab vedotin plus Pembrolizumab (EVP) compared to platinum-based chemotherapy in patients (pts) that received first-line (1L) therapy for metastatic urothelial carcinoma (mUC). Since presentation the data September 2023 EVP was considered a new standard care (SOC) however only approved Europe August 2024. We analyzed and safety outcomes pts treated with outside clinical trials. Methods:...

10.1200/jco.2025.43.5_suppl.715 article EN Journal of Clinical Oncology 2025-02-10

Background and Purpose —Gray-scale harmonic imaging is the first method to visualize blood perfusion capillary flow with ultrasound after intravenous contrast agent application. The purpose of present study was evaluate potential transient response second (TRsHI) assess normal echo characteristics in different brain areas by transcranial ultrasound. Methods —In 18 patients without cerebrovascular diseases, TRsHI examinations were performed bilaterally use transtemporal approach application...

10.1161/01.str.29.9.1901 article EN Stroke 1998-09-01
Coming Soon ...